TY  - JOUR

T1  - Time on Treatment and Survival Outcomes for Patients Treated With First-line Osimertinib<i>vs</i>. Other Tyrosine Kinase Inhibitors, for EGFR Mutation-positive Metastatic Non-small Cell Lung Cancer: Real-world Experience Data

JO  - Anticancer Research

UR  - https://doi.org/10.21873/anticanres.16809

PY  - 2023/12/30

AU  - MOSER SS

AU  - APTER L

AU  - SOLOMON J

AU  - CHODICK G

AU  - WOLLNER M

AU  - SIEGELMANN-DANIELI N

ED  - 

DO  - DOI: 10.21873/anticanres.16809

PB  - Anticancer Research USA Inc.

VL  - 44

IS  - 1

SP  - 257

EP  - 265

Y2  - 2025/02/05

ER  -